Background:

IC50: N/A

Sennoside A is a dianthrone glycoside isolated from Rhei Rhizoma and senna leaf. Sennoside A and B have identical molecular weights and formulae. Sennosides were known as laxatives causing purgative actions through the biotransformation of rhein anthrone. Sennoside A was reported to have regionally differential effects on spontaneous contractions of colon.

In vitro: The gastroprotective activities of sennoside A was found to be due to the up-regulation of PGE2 and the inhibitions of H+/K+-ATPase activity. When measured the H+/K+-ATPase activities of sennoside A, the positive control exhibited inhibitions of 41.1% and 42.4% at 50 μM and 100 μM, whereas sennoside A showed dose-dependent inhibitions of 17.3% and 27.1% at 50 μM and 100 μM [1].

In vivo: In a rat model, sennoside A reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A increased PGE2 in a concentration-dependent manner. Moreover, in the intestinal transporting and gastric emptying rate experiment, sennoside A was found to accelerate such GI motility. These results suggested sennoside A possessed significant gastroprotective activities and it might be useful for the gastric disease treatment [1].

Clinical trial: N/A

Reference:
[1] In Young HwangandChoon Sik Jeong.  Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2and the Inhibition of H+/K+-ATPase Biomol Ther (Seoul). 2015 Sep; 23(5): 458–464.